Be Biopharma

aid: be-biopharma
name: Be Biopharma
description: 'Be Biopharma (Be Bio) is a Cambridge, Massachusetts clinical-stage biotechnology company founded in October
  2020 by Longwood Fund together with B cell engineering researchers David Rawlings, M.D. and Richard James, Ph.D. of Seattle
  Children''s Research Institute. The company develops engineered B Cell Medicines (BCMs) — a patient''s own B cells engineered
  to produce a therapeutic protein — for genetic disease, cancer and other serious conditions. Its lead candidate, BE-101,
  inserted a functional Factor IX gene into primary human B cells for hemophilia B and held FDA Orphan Drug and Fast Track
  designations; a second program, BE-102, targeted hypophosphatasia. The company raised $82M in October 2024 and $92M in a
  January 2025 Series C, dosed the first participant in the Phase 1/2 BeCoMe-9 trial in July 2025, and terminated that trial
  in June 2026 for stated strategic business reasons. Be Biopharma is a therapeutics developer, not a software company: it
  has never published a developer program, API, SDK or machine-readable contract.'
url: https://raw.githubusercontent.com/api-evangelist/be-biopharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: none
  source:
  - security
  generated: '2026-11-06'
  method: derived
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Life Sciences
- Cell Therapy
- Gene Therapy
- Pharmaceuticals
- Healthcare
- Clinical Trials
- Rare Disease
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/be-biopharma-domain-security.yml
- type: LLMsTxt
  url: llms/be-biopharma-llms.txt
- type: Website
  url: https://be.bio/
- type: Archive
  url: https://web.archive.org/web/20260513184102/https://be.bio/
- type: LinkedIn
  url: https://www.linkedin.com/company/be-biopharma-inc
- type: SecondaryMarket
  url: https://forgeglobal.com/be-biopharma_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: defunct
  detail: Be Biopharma's own domain be.bio no longer resolves — its authoritative nameservers (ns1.g02.cfdns.net) return SOA
    only for both the apex and www, so there is no host left to probe; the site was last archived 2026-05-13, the company
    terminated its lead BeCoMe-9 hemophilia B trial in June 2026, and LinkedIn now lists a single employee.
  evidence:
  - url: https://be.bio/
    status: 0
  - url: https://www.be.bio/.well-known/security.txt
    status: 404
  - url: https://www.be.bio/.well-known/openid-configuration
    status: 404
  - url: https://www.be.bio/.well-known/ai-plugin.json
    status: 404
  - url: https://web.archive.org/web/20260513184102/https://be.bio/
    status: 200
  - url: https://api.github.com/search/users?q=bebiopharma+OR+be-biopharma
    status: 200
  checked: '2026-08-06'
x-lifecycle:
  state: shuttered
  reason: domain-does-not-resolve
  observed: '2026-09-27'
  detail: The company's own domain returned no A or AAAA record when probed. This is an observation about the domain, not
    a request from the company.
  indexed: false